Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 9/20 | 0.52 |
| ▸ | CYP11B1 | P15538 | 8/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.49 |
| ▸ | CYP17A1 | P05093 | 4/20 | 0.49 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.41 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.41 |
| ▸ | HTR1D | P28221 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.40 |
| ▸ | PTGES | O14684 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6846202 | 0.90 | HTR1D (0.49) | CYP11B2CYP11B1CYP19A1CYP17A1CAPN1 | |
| SCHEMBL6657245 | 0.85 | CYP11B2 (0.52) | CYP11B2CYP11B1CYP19A1CYP17A1GRM2 | |
| SCHEMBL6845513 | 0.81 | CYP11B2 (0.49) | CYP11B2CYP11B1CYP19A1CYP17A1GRM2 | |
| SCHEMBL6657591 | 0.81 | CYP11B2 (0.56) | CYP11B2CYP11B1CYP19A1CYP17A1GRM2 | |
| SCHEMBL6657515 | 0.81 | CYP11B2 (0.54) | CYP11B2CYP11B1CYP19A1CYP17A1GRM2 | |
| SCHEMBL6846125 | 0.81 | CYP11B2 (0.59) | CYP11B2CYP11B1CYP19A1CYP17A1GRM2 | |
| SCHEMBL6660298 | 0.80 | CYP11B2 (0.55) | CYP11B2CYP11B1CYP19A1CYP17A1GRM2 | |
| SCHEMBL6845959 | 0.79 | CYP11B1 (0.54) | CYP11B2CYP11B1CYP19A1CYP17A1GRM2 | |
| SCHEMBL6659220 | 0.78 | CYP11B1 (0.53) | CYP11B2CYP11B1CYP19A1CYP17A1HTR1D | |
| SCHEMBL22515743 | 0.78 | CYP11B2 (0.53) | CYP11B2CYP11B1CYP19A1CYP17A1GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040236110-A1 | Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors | BAYER PHARMACEUTICALS CORPORATION | 2004-11-25 | — | — | US | disclosed |
| US-6773573-B2 | ELECTROLYTIC CELLS; BATH MIXTURE CONTAINING ALCOHOLS; STABILITY | SHIPLEY COMPANY, L.L.C. | 2004-08-10 | — | — | US | disclosed |
| EP-1432698-A2 | SUBSTITUTED 3-PYRIDYL INDOLES AND INDAZOLES AS C17,20 LYASE INHIBITORS | Bayer Pharmaceuticals Corporation (US) | 2004-06-30 | — | — | EP | disclosed |
| US-20030102226-A1 | Plating bath and method for depositing a metal layer on a substrate | SHIPLEY COMPANY, L.L.C. | 2003-06-05 | — | — | US | disclosed |
| WO-2003027094-A2 | SUBSTITUTED 3-PYRIDYL INDOLES AND INDAZOLES AS C17,20 LYASE INHIBITORS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040236110-A1 | Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors | CYP17A1, IDO1, CYP21A2 | CYP11B2 53/4885CYP11B1 30/4885CYP19A1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.